OpenAI just released a report about healthcare drawn from anonymized chatbot conversations. The title could double as one of ...
Pegcetacoplan significantly reduces proteinuria in patients with recurrent C3 glomerulopathy, or primary immune-complex ...
Blowing Money Fast is coming back with its second season on Friday, January 16, with new episodes to stream weekly on Fridays ...
2d
The 100 Best Companies for Fully Remote Jobs in 2026 Named in Virtual Vocations’ 10th Annual List
Enhanced technology and human expertise drive 49% increase in vetted remote job postings to Virtual Vocations database. The 49% increase in fully remote job postings we saw in 2025 is a direct result ...
The gap between the Astros' ace, Hunter Brown, and the rest of their rotation narrows with the addition of Imai.
Omeros’ Yartemlea gets US FDA approval to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy: Seattle Monday, December 29, 2025, 12:00 Hrs [IST] Omer ...
Despite Biff Poggi’s comments that there could be 25 new opt-outs for the Citrus Bowl, everyone made the trip to Orlando.
Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: YARTEMLEA(R) is the only approved treatment for hematopoietic stem cell ...
Learn how you can maximize your travel rewards by pairing the Capital One Venture X and the Chase Sapphire Preferred.
CACI International Inc ( CACI) M&A Call December 22, 2025 8:30 AM EST ...
Investing.com -- Q32 Bio Inc (NASDAQ:QTTB) stock surged 94% in premarket trading Monday after the clinical-stage biotechnology company announced the sale of its Phase 2 complement inhibitor, ADX-097, ...
(RTTNews) - Biotechnology company Q32 Bio, Inc. (QTTB) announced Monday it has sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics, Inc. (AKBA). ADX-097, the lead product candidate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback